Published on 02/12/2025

Lessons from Regulator Signals on AI

Introduction to AI/ML Model Validation in GxP Analytics

The integration of Artificial Intelligence (AI) and Machine Learning (ML) in Good Automated Manufacturing Practice (GxP) analytics has transformed the pharmaceutical industry. The application of these technologies introduces both opportunities and challenges with respect to regulatory compliance. The aim of this tutorial is to guide pharma professionals through the complexities of AI/ML model validation, focusing on risk management, intended use assessment, data readiness curation, bias and fairness testing, model verification and validation, explainability, and governance and security frameworks.

Understanding the intricacies involved is essential given the evolving landscape regulated by entities such as the FDA, EMA, MHRA, and under shared guidance documents from organizations like PIC/S.

1. Risk Assessment in AI/ML Model Validation

A core requirement in ensuring compliance and operational integrity is a thorough risk assessment tailored to the specific applications of AI/ML models. The first step in this process is to identify the types of risks associated with AI/ML applications, including:

• Technical risks related to model performance and data integrity.
• Operational risks regarding end-user interpretation and decision-making.
• Regulatory risks from non-compliance with guidance and laws.

To effectively manage these risks, organizations can employ risk-based thinking as set forth in GxP regulations. It involves engaging various stakeholders to assess the intended use and implications of AI/ML outputs systematically, which will also guide the implementation of critical controls as part of a quality management system.

Develop a risk matrix that categorizes risks as low, medium, or high. This will enable prioritizing validation activities based on the potential impact of each risk. In the context of AI/ML, special attention should be given to intended use risk, where different use cases might have distinct risk profiles.

2. Intended Use & Data Readiness Curation

Understanding the intended use of models is paramount in validating AI/ML implementations. Here, you can classify AI/ML applications into multiple categories based on their intended use:

• Supportive decision-making.
• Autonomous decision-making.
• Predictive analytics.

For each application, implement comprehensive data readiness criteria in both data acquisition and preprocessing stages. Documentation detailing these processes will serve as essential evidence for compliance. This phase involves:

• Defining data sources and reliability metrics.
• Implementing curation strategies to handle missing or biased data.
• Challenges in ensuring data quality and consistency.

To mitigate intended use risk, conduct a gap analysis between data availability and quality versus model requirements. Well-documented processes will enhance transparency and defend the validity of the model during audits and inspections.

3. Bias and Fairness Testing

A critical facet of AI/ML validation is the identification and mitigation of bias. Bias can lead to systematic errors in predictions, which may adversely affect patient safety or product quality. To address these challenges, it is important to implement fairness testing methodologies:

• Define fairness criteria relevant to the specific context of the application.
• Incorporate diverse datasets that reflect the target population.
• Utilize statistical methods to test for bias at various levels.

Regularly evaluate and revise models based on bias and fairness audit trails. Documentation of each testing cycle will demonstrate accountability and adherence to regulatory expectations from authorities like EMA and MHRA, especially in light of evolving regulatory landscapes around AI/ML.

4. Model Verification and Validation (V&V) Processes

Model verification and validation are essential components of the AI/ML lifecycle. Verification confirms whether the model performs as intended under defined scenarios, while validation assures it meets the specified requirements in actual operational environments. Incorporate these steps into the V&V process:

• **Verification**: Conduct functional and performance testing to assure that the AI/ML model operates according to predefined specifications. This stage should include robustness checks against outlier data.
• **Validation**: Transition from controlled settings to real-world environments. Involve stakeholders in assessing outcomes against regulatory requirements and clinical relevance.

Document the entire V&V process in accordance with relevant guidelines, including 21 CFR Part 11 and GAMP 5, to support an audit-friendly environment. Establish audit trails for both training and inference processes to ensure accountability and traceability.

5. Explainability in AI/ML Models (XAI)

The notion of explainability in AI/ML models, often referred to as Explainable Artificial Intelligence (XAI), is increasingly viewed as a crucial aspect of compliance. Regulatory bodies demand that stakeholders can rationally understand how AI-driven decisions were arrived at, to ensure system reliability and safeguard against trust erosion.

Incorporate explainability mechanisms through the following steps:

• Adopt algorithmic techniques that allow for post-hoc interpretability of model predictions.
• Provide transparent documentation on model design choices, particularly concerning parameter selections and dataset characteristics.
• Facilitate user-friendly interfaces that enhance understanding of model outputs and enable an informed decision-making process.

Compiling explainable evidence will facilitate compliance discussions with regulatory agencies and strengthen the justification of AI/ML applications in real-world settings.

6. Drift Monitoring & Re-Validation of AI/ML Models

Machine learning models are not static; they require continuous monitoring to ensure they adapt adequately over time, particularly as new data become available. Drift monitoring refers to the processes of assessing performance to recognize when a model is becoming less effective or biased due to changing input data conditions.

Implement the following actions for effective drift monitoring:

• Establish key performance indicators (KPIs) to track model performance metrics over time accurately.
• Schedule routine reviews to assess shifts in data distributions and their impacts on the model.
• Plan a framework for re-validation following notable drifts to ensure the model continues to meet intended use requirements.

Documentation of drift analyses and consequent actions should be detailed to support the integrity of the decision-making process when determining if a model requires retraining or replacement.

7. Documentation & Audit Trails

A critical element for compliance in AI/ML validation is the systematic documentation of processes and results. This should document each validation, data preprocessing, bias testing, and monitoring activity. According to the guidelines under 21 CFR Part 11 and Annex 11, ensure that documentation is:

• Complete and accurate.
• Easily accessible and in a format compliant with regulatory requirements.
• Includes audit trails of changes made, especially concerning model iterations and data modifications.

Fostering a culture of thorough documentation will enhance communication among stakeholders and serve as a roadmap for both internal assessments and regulatory audits.

8. AI Governance & Security in Pharmaceutical Applications

Finally, establishing a governance and security framework is vital to safeguard AI/ML models from unauthorized access and modification while ensuring compliance with ethical standards. This involves:

• Creating an organizational structure that includes representation from QA, IT, and data governance teams.
• Implementing data security measures aligning with prevailing standards such as GDPR in Europe.
• Fostering ethical use policies to ensure AI models are developed and deployed according to established best practices.

Regularly revisiting your governance framework and security protocols will enhance stakeholder confidence and align with evolving regulatory expectations.

Conclusion

The integration of AI and ML in pharmaceutical applications poses significant opportunities, alongside complex challenges regarding validation and compliance. By adopting a structured approach to risk management, intended use assessment, bias testing, model V&V, explainability, drift monitoring, and robust documentation, organizations can successfully navigate the regulatory landscape. Ultimately, establishing strong governance and security frameworks will enhance trust and reliability in AI-driven healthcare solutions.

As the industry continues to evolve, remaining compliant with the latest regulatory frameworks and guidelines will ensure that AI/ML technologies can be harnessed in a manner consistent with both product efficacy and patient safety.